Abcellera Biologics Inc

$3.15
(as of Jun 12, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Abcellera Biologics Inc

Stock Price
$3.15
Ticker Symbol
ABCL
Exchange
NASDAQ

Industry Information for Abcellera Biologics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Abcellera Biologics Inc

Website
https://www.abcellera.com
Country
USA
Full Time Employees
596

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Fundamentals for Abcellera Biologics Inc

Market Capitalization
$901,424,640
EBITDA
$-231,196,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
27.47
Earnings per Share
$-0.67
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
298,484,992
Percent Owned by Insiders
22.97%
Percent Owned by Institutions
44.71%
52-Week High
52-Week Low

Technical Indicators for Abcellera Biologics Inc

50-Day Moving Average
200-Day Moving Average
RSI
82.67
ATR
0.18

Analyst Ratings for Abcellera Biologics Inc

Strong Buy
6
Buy
2
Hold
1
Sell
0
Strong Sell
0

News About Abcellera Biologics Inc

Jun 9, 2025, 9:13 AM EST
We came across a bullish thesis on AbCellera Biologics Inc. See more.
Jun 3, 2025, 8:05 AM EST
The market has climbed by 2.0% over the past week, with every sector up, and in the last year, it has risen by 12%, showcasing a robust performance. See more.
Jun 2, 2025, 6:45 PM EST
Investors were surely discovering drug discovery company AbCellera Biologics(NASDAQ: ABCL) as the trading week kicked off on Monday. See more.
Jun 2, 2025, 6:45 PM EST
Key Points See more.